Interferon Beta-1a Treatment in Htlv-1-associated Myelopathy/tropical Spastic Paraparesis: a Case Report

Abstract

Here a young patient (< 21 years of age) with a history of infective dermatitis is described. The patient was diagnosed with myelopathy associated with HTLV-1/tropical spastic paraparesis and treated with interferon beta-1a. The disease was clinically established as HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP), and laboratory tests confirmed the presence of antibodies to HTLV-1 in the cerebrospinal fluid (CSF). Mumps, cytomegalovirus, Epstein-Barr virus, schistosomiasis, herpes virus 1 and 2, rubella, measles, varicella-zoster toxoplasmosis, hepatitis, HIV, and syphilis were excluded by serology. The patient was diagnosed with neurogenic bladder and presented with nocturia, urinary urgency, paresthesia of the lower left limb, a marked reduction of muscle strength in the lower limbs, and a slight reduction in upper limb strength. During the fourth week of treatment with interferon beta-1a, urinary urgency and paresthesia disappeared and clinical motor skills improved.

Extracted Key Phrases

Cite this paper

@inproceedings{Viana2014InterferonBT, title={Interferon Beta-1a Treatment in Htlv-1-associated Myelopathy/tropical Spastic Paraparesis: a Case Report}, author={Graça Maria de Castro Viana and Marcos Antonio Cust{\'o}dio Neto da Silva and Victor Lima de Souza and Nat{\'a}lia Barbosa da Silva Lopes and Diego Luz Felipe da Silva and Maria do Desterro Soares Brand{\~a}o Nascimento}, booktitle={Revista do Instituto de Medicina Tropical de São Paulo}, year={2014} }